Akesson B, Henningsson R, Salehi A, Lundquist I
Department of Pharmacology, University of Lund, Lund, Sweden.
J Endocrinol. 1999 Oct;163(1):39-48. doi: 10.1677/joe.0.1630039.
We have studied, by a combined in vitro and in vivo approach, the relation between the inhibitory action of N(G)-nitro-l-arginine methyl ester (L-NAME), a selective inhibitor of nitric oxide synthase (NOS), on the activity of islet constitutive NOS (cNOS) and glucose regulation of islet hormone release in mice. The cNOS activity in islets incubated in vitro at 20 mM glucose was not appreciably affected by 0.05 or 0.5 mM L-NAME, but was greatly suppressed (-60%) by 5 mM L-NAME. Similarly, glucose-stimulated insulin release was unaffected by the lower concentrations of L-NAME but greatly enhanced in the presence of 5 mM of the NOS inhibitor. In incubated islets inhibition of cNOS activity resulted in a modestly enhanced insulin release in the absence of glucose, did not display any effect at physiological or subphysiological glucose concentrations, but resulted in a markedly potentiated insulin release at hyperglycaemic glucose concentrations. In the absence of glucose, glucagon secretion was suppressed by L-NAME. The dynamics of glucose-induced insulin release and (45)Ca(2+) efflux from perifused islets revealed that L-NAME caused an immediate potentiation of insulin release, and a slight increase in (45)Ca(2+) efflux. In islets depolarized with 30 mM K(+) in the presence of the K(+)(ATP) channel opener, diazoxide, L-NAME still greatly potentiated glucose-induced insulin release. Finally, an i.v. injection of glucose to mice pretreated with L-NAME was followed by a markedly potentiated insulin response, and an improved glucose tolerance. In accordance, islets isolated directly ex vivo after L-NAME injection displayed a markedly reduced cNOS activity. In conclusion, we have shown here, for the first time, that biochemically verified suppression of islet cNOS activity, induced by the NOS inhibitor L-NAME, is accompanied by a marked potentiation of glucose-stimulated insulin release both in vitro and in vivo. The major action of NO to inhibit glucose-induced insulin release is probably not primarily linked to changes in Ca(2+) fluxes and is exerted mainly independently of membrane depolarization events.
我们采用体外和体内相结合的方法,研究了一氧化氮合酶(NOS)的选择性抑制剂N(G)-硝基-L-精氨酸甲酯(L-NAME)对胰岛组成型NOS(cNOS)活性的抑制作用与小鼠胰岛激素释放的葡萄糖调节之间的关系。在20 mM葡萄糖条件下体外孵育的胰岛中,0.05或0.5 mM的L-NAME对cNOS活性没有明显影响,但5 mM的L-NAME可使其显著抑制(-60%)。同样,较低浓度的L-NAME不影响葡萄糖刺激的胰岛素释放,但在存在5 mM NOS抑制剂时则显著增强。在孵育的胰岛中,cNOS活性的抑制在无葡萄糖时导致胰岛素释放适度增强,在生理或亚生理葡萄糖浓度下无任何作用,但在高血糖葡萄糖浓度下导致胰岛素释放明显增强。在无葡萄糖时,L-NAME抑制胰高血糖素分泌。葡萄糖诱导的胰岛素释放动力学以及来自灌流胰岛的(45)Ca(2+)外流显示,L-NAME导致胰岛素释放立即增强,且(45)Ca(2+)外流略有增加。在存在K(+)(ATP)通道开放剂二氮嗪的情况下,用30 mM K(+)使胰岛去极化,L-NAME仍能显著增强葡萄糖诱导的胰岛素释放。最后,对用L-NAME预处理的小鼠静脉注射葡萄糖后,胰岛素反应显著增强,葡萄糖耐量得到改善。相应地,在注射L-NAME后直接从体内分离的胰岛显示cNOS活性明显降低。总之,我们首次在此表明,由NOS抑制剂L-NAME诱导的经生化验证的胰岛cNOS活性抑制,在体外和体内均伴随着葡萄糖刺激的胰岛素释放显著增强。NO抑制葡萄糖诱导的胰岛素释放的主要作用可能主要不是与Ca(2+)通量的变化相关,且主要独立于膜去极化事件发挥作用。